Abstracts tagged "risk assessment"

Abstract Number: 0084 • ACR Convergence 2022
Facilitators and Barriers of Vaccine Uptake in Patients with Chronic Inflammatory Rheumatic Disease: A Scoping Review
Silke Neusser¹, Anja Neumann¹, Christian Speckemeier¹, Pauline zur NIeden¹, Sarah Schlierenkamp¹, Anke Walendzik¹, Ute Karbach², Ioana Andreica³, Kristina Vaupel⁴, Xenofon Baraliakos⁵ and Uta Kiltz⁴, ¹Essener Forschungsinstitut für Medizinmanagement, Essen, Germany, ²Institute of Medical Sociology, Health Services Research and Rehabilitation Science (IMVR), Cologne, Germany, ³Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: Patients with chronic inflammatory rheumatic diseases (CIRD) remain underrepresented in receiving vaccinations despite being disproportionately affected by infectious complications. The aim of our study…
Abstract Number: 1342 • ACR Convergence 2022
Quality Improvement: Communicating Risk Regarding JAK Inhibitor Use in Rheumatology Patients
Reid Weisberg¹, Brett Capel¹, Annabelle Guo¹, Komal Patel¹, Rashmi Arora², Swathi Reddy³ and Una Makris⁴, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Dallas VA Medical Center / University of Texas Southwestern Medical Center, Dallas, TX, ³Dallas VA Medical Center / University of Texas Southwestern Medical Center, Colleyville, TX, ⁴UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: In September 2021, the FDA updated its boxed warnings for Janus Kinase (JAK) inhibitors to include increased risk of major adverse cardiac events (MACE)…
Abstract Number: 0205 • ACR Convergence 2022
Virtually Training Peer Coaches to Use Motivational Interviewing Skills: Processes from a Rheumatoid Arthritis Intervention Training Program
Mackenzie Brown¹, Yuliana Domínguez Páez², Assem Jabri³, Geyanne Lui⁴, Joan Weiner³, Aberdeen Allen⁵, Tien Sydnor-Campbell⁶, Shelley fritz³, Megan Creasman⁷, Shanthini Kasturi⁸, Monika Safford³ and Iris Navarro-Millan³, ¹Weill Cornell Medicine, Brooklyn, NY, ²Weill Cornell Medicine, Bronx, NY, ³Weill Cornell Medicine, New York, NY, ⁴Albert Einstein College of Medicine, New York, NY, ⁵Weill Cornell Medicine, Parlin, ⁶Weill Cornell Medicine, Philedelphia, ⁷NYP-Weill Cornell, New York, NY, ⁸Tufts Medical Center, Boston, MA
Background/Purpose: Peer coaching interventions are effective in helping individuals with chronic conditions understand and manage their disease. Most peer coach training programs occur in person,…
Abstract Number: 1365 • ACR Convergence 2022
Adverse Events Associated with Belimumab Use in Pediatric Patients: Review and Analyses of the FDA Adverse Event Reporting System Database
Ivone Kim, Debra Ryan, Carmen Cheng and Cindy Kortepeter, Food and Drug Administration, Silver Spring, MD
Background/Purpose: FDA approved belimumab, the first targeted biological treatment for SLE, in March 2011 for adults with active, seropositive SLE receiving standard therapy. The indicated…
Abstract Number: 0262 • ACR Convergence 2022
Predictors of Fragility Fracture Amongst Patients with Rheumatoid Arthritis: An Observational Cohort Study
Seema Sharma¹ and Marwan Bukhari², ¹Lancaster Royal Infirmary, Lancaster, United Kingdom, ²University Hospitals of Morecambe Bay NHS Trust, Lancaster, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is associated with reduced bone mineral density and almost one third of this population have osteoporosis leading to increased risk of…
Abstract Number: 1389 • ACR Convergence 2022
The New Serum Synovial Biochemical Marker HELIX-III Predicts Radiological Progression in Early Arthritis Independently of Usual Risk Factors
Patrick Garnero¹, Evelyne Gineyts¹, Jean-Charles Rousseau¹, Pascal Richette², Jérémie SELLAM³ and Roland Chapurlat¹, ¹INSERM 1033, Lyon, France, ²Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, ³Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France
Background/Purpose: The prognosis of rheumatoid arthritis (RA) is highly variable across patients (P.) and difficult to predict. Usual risk factors, e.g., radiological joint damage, increased…
Abstract Number: 0292 • ACR Convergence 2022
Malignancy in the Upadacitinib Clinical Trial Programs for Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Andrea Rubbert-Roth¹, Adriana Kakehasi², Tsutomu Takeuchi³, Marc Schmalzing⁴, Hannah Palac⁵, Jianzhong Liu⁵, Samuel Anyanwu⁵, Ralph Lippe⁶ and Jeffrey Curtis⁷, ¹Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland, ²Federal University of Minas Gerais, Hospital das Clínicas, Belo Horizonte, Brazil, ³Keio University and Saitama Medical University, Tokyo, Japan, ⁴University Hospital Wuerzburg, Wuerzburg, Germany, ⁵AbbVie, Inc., North Chicago, IL, ⁶AbbVie, Inc, Wiesbaden, Germany, ⁷University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Increased risk of malignancies has been associated with chronic inflammation, as well as immunosuppressive and immunomodulatory therapies. The objective of this analysis is to…
Abstract Number: 1396 • ACR Convergence 2022
Risk of Hospitalized Infections in Older Elderly Rheumatoid Arthritis Patients Treated with Biological/Targeted Synthetic DMARDs: Evaluation Using Data from a Japanese Claims Database
Masayoshi Harigai¹, Takao Fujii², Ryoko Sakai³, Ataru Igarashi⁴, Ayako Shoji⁵, Hiroko Yamaguchi⁶, Katsuhiko Iwasaki⁶, Misako Makishima⁷, Amika Yoshida⁷, Norihiro Okada⁷, Katsuhisa Yamashita⁷ and Yutaka Kawahito⁸, ¹Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ²Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan, ³Department of Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan, ⁴Department of Health Economics & Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan; Unit of Public Health and Preventive Medicine, Yokohama City University of Medicine, Kanagawa, Japan, ⁵Medilead Inc., Tokyo, Japan; Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan; Healthcare Consulting Inc., Tokyo, Japan, Shinjuku-ku, Japan, ⁶Medilead Inc., Tokyo, Japan, Shinjuku-ku, Japan, ⁷Chugai Pharmaceutical Co., Ltd., Chuo-ku, Tokyo, Japan, ⁸Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, Kyoto, Kyoto, Japan
Background/Purpose: Safety evidence of biological or targeted synthetic DMARDs (b/tsDMARDs) is still insufficient in older elderly ( >=75 years old (y/o)) patients with rheumatoid arthritis…
Abstract Number: 0510 • ACR Convergence 2022
MACE and VTE Across Upadacitinib Clinical Trial Programs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Christina Charles-Schoeman¹, Ernest Choy², Iain B McInnes³, Eduardo Mysler⁴, Peter Nash⁵, Kunihiro Yamaoka⁶, Ralph Lippe⁷, Nasser Khan⁸, Anna K Shmagel⁹, Hannah Palac⁹, Jessica Suboticki¹⁰ and Jeffrey Curtis¹¹, ¹Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA, ²Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ³Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ⁴Department of Rheumatology, OMI (Medical Research Organization), Buenos Aires, Argentina, ⁵School of Medicine, Griffith University, Sunshine Coast, Australia, ⁶Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ⁷AbbVie, Inc, Wiesbaden, Germany, ⁸AbbVie, Inc., Abbott Park, IL, ⁹AbbVie, Inc., North Chicago, IL, ¹⁰AbbVie, Inc., Mettawa, IL, ¹¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Patients with untreated immune-mediated inflammatory diseases, such as RA, PsA, and AS, are at increased risk for major adverse cardiovascular events (MACE) and venous…
Abstract Number: 1400 • ACR Convergence 2022
Machine Learning Identifies Molecular Phenotypes That Predict Incident Cardiovascular Disease in Patients with Rheumatoid Arthritis
Tate Johnson¹, Rebekah Gundry², Merry Lindsey², Punyasha Roul³, Yangyuna Yang², Joshua Baker⁴, Brian Sauer⁵, Grant Cannon⁶, Geoffrey Thiele², Ted Mikuls⁷ and Bryant England², ¹University of Nebraska Medical Center, Elkhorn, NE, ²University of Nebraska Medical Center, Omaha, NE, ³UNMC, Omaha, NE, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶Retired, Salt Lake City, UT, ⁷Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cardiovascular disease (CVD) remains the leading cause of death in patients with rheumatoid arthritis (RA). General population CVD risk calculators underestimate risk in RA,…
Abstract Number: 0716 • ACR Convergence 2022
Posttraumatic Stress Disorder Symptoms in Systemic Autoimmune Rheumatic Disease Patients During the Early COVID-19 Pandemic
Jack Ellrodt¹, Emily G Oakes¹, Laura Kubzansky², Karestan Koenen², Hongshu Guan¹ and Karen Costenbader¹, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard TH Chan School of Public Health, Boston, MA
Background/Purpose: Posttraumatic Stress Disorder (PTSD), a complex psychiatric disorder that can result from experiencing or witnessing a traumatic event, such as an accident, assault, or…
Abstract Number: 1429 • ACR Convergence 2022
Acute Cardiovascular Events Risk in Rheumatoid Arthritis Patients Treated with Tofacitinib or TNF Inhibitors, a Nationwide Cohort Study: RELATION Study
jacques-eric gottenberg¹, Nadir Mammar², Meriem Kessouri², Jeremie RUDANT², nada Assi³, Benjamin grenier³ and julien kirchgesner⁴, ¹Strasbourg University Hospital, Strasbourg, France, ²Pfizer, Paris, France, ³HEVA, Lyon, France, ⁴AP-HP, Paris, France
Background/Purpose: Patients with IMID, and notably patients with rheumatoid arthritis (RA), are at increased risk of major adverse cardiovascular event (MACE) compared with the general…
Abstract Number: 0723 • ACR Convergence 2022
Risk of Major Adverse Cardiovascular and Venous Thromboembolism Events in Patients with Rheumatoid Arthritis Exposed to JAK Inhibitors versus Adalimumab: A Nationwide Cohort Study
Lea Hoisnard¹, Laura Pina Vegas², Rosemary Dray-Spira³, Alain Weill³, Mahmoud Zureik³ and Emilie sbidian⁴, ¹Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique-Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Créteil, France, ²Service de Rhumatologie, AP-HP, Hôpital Henri Mondor, Créteil, France, ³EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for Medicines and Health Products Safety, French National Health Insurance, Saint-Denis, France, ⁴Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France
Background/Purpose: To assess the risk of major adverse cardiovascular events (MACEs) and venous thromboembolism events (VTEs) among patients initiating a Janus kinase inhibitor (JAKi) (tofacitinib…
Abstract Number: 1466 • ACR Convergence 2022
Cardiovascular Risk Assessment in Patients with Systemic Lupus Erythematosus: Comparison Between QRISK and aGAPSS Scores
Alice Barinotti¹, Massimo Radin¹, Irene Cecchi², Silvia Grazietta Foddai¹, Simone Baldovino¹, Elisa Menegatti¹, Daniela Rossi¹, Vittorio Modena¹, Dario Roccatello¹ and Savino Sciascia², ¹University of Turin, Turin, Italy, ²University of Turin, Torino, Italy
Background/Purpose: Cardiovascular diseases (CVDs) represent one of the most life-threatening conditions that can affect SLE patients. Assessing the potential CVD risk of these patients is…
Abstract Number: 0732 • ACR Convergence 2022
Application of Natural Language Processing to Identify Varicella Zoster Infection in Clinical Notes
Austin Ho¹, Zara Izadi², Gabriela Schmajuk³, Jinoos Yazdany⁴, Suzanne Tamang⁵ and Milena Gianfrancesco⁶, ¹University of California, Berkeley, Berkeley, CA, ²University of California San Francisco, San Francisco, CA, ³UCSF / SFVA, San Francisco, CA, ⁴UCSF, San Francisco, CA, ⁵Stanford Center for Population Health Sciences, Redwood City, CA, ⁶University of California, San Francisco, San Francisco, CA
Background/Purpose: Varicella zoster virus (VZV) infection can be associated with significant morbidity in immunosuppressed individuals. However, infections of VZV are often documented in unstructured fields…

« Previous Page
1
…
6
7
8
9
10
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].